Provides update on Tesomet and AN363

Saniona, a leading biotech company within ion-channel research, announces new clinical data, which strongly supports the use of Tesomet, a combination of Tesofensine and Metoprolol, for treatment of type 2 diabetes. Datamining of the results from previous human clinical trials shows that Tesofensine reduces glycemic parameters in prediabetes individuals participating in a Phase 2 study and that Metoprolol blunts the increase in heart rate caused by Tesofensine in volunteers in a Phase 1 study.

The release as fetched from its publisher. saniona.com ↗